Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy.
Biomarkers
Hereditary cerebral amyloid angiopathy cerebrospinal fluid
Matrix metalloproteinases
Sporadic cerebral amyloid angiopathy
Tissue inhibitors of matrix metalloproteinases
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
30 01 2023
30 01 2023
Historique:
received:
16
12
2022
accepted:
17
01
2023
entrez:
31
1
2023
pubmed:
1
2
2023
medline:
2
2
2023
Statut:
epublish
Résumé
To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or hereditary cerebral amyloid angiopathy (CAA). CSF concentrations of the matrix metalloproteinases MMP-2, MMP-9 and MMP-14, as well as the tissue inhibitors of metalloproteinases TIMP-1, TIMP-2 and TIMP-3, were determined using immunoassays. These assays were applied to two, independent study groups of sporadic CAA (sCAA) (n = 28/43) and control subjects (n = 40/40), as well as to groups of pre-symptomatic (n = 11) and symptomatic hereditary Dutch-CAA (D-CAA) patients (n = 12), and age-matched controls (n = 22/28, respectively). In the sCAA/control cohorts, inconsistent differences were found for individual MMPs and TIMPs, but MMP-2/TIMP-2 (discovery/validation: p = 0.004; p = 0.02) and MMP-14/TIMP-2 ratios (discovery/validation: p < 0.001; p = 0.04) were consistently decreased in sCAA, compared to controls. Moreover, MMP-14 was decreased in symptomatic D-CAA (p = 0.03), compared to controls. The MMP-14/TIMP-1 (p = 0.03) and MMP-14/TIMP-2 (p = 0.04) ratios were decreased in symptomatic D-CAA compared to controls and also compared to pre-symptomatic D-CAA (p = 0.004; p = 0.005, respectively). CSF MMP-2/TIMP-2 and MMP-14/TIMP-2 were consistently decreased in sCAA, compared to controls. Additionally, MMP-14/TIMP-2 levels were also decreased in symptomatic D-CAA, compared to both pre-symptomatic D-CAA and controls, and can therefore be considered a biomarker for sporadic and late-stage hereditary forms of CAA.
Sections du résumé
BACKGROUND
To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or hereditary cerebral amyloid angiopathy (CAA).
METHODS
CSF concentrations of the matrix metalloproteinases MMP-2, MMP-9 and MMP-14, as well as the tissue inhibitors of metalloproteinases TIMP-1, TIMP-2 and TIMP-3, were determined using immunoassays. These assays were applied to two, independent study groups of sporadic CAA (sCAA) (n = 28/43) and control subjects (n = 40/40), as well as to groups of pre-symptomatic (n = 11) and symptomatic hereditary Dutch-CAA (D-CAA) patients (n = 12), and age-matched controls (n = 22/28, respectively).
RESULTS
In the sCAA/control cohorts, inconsistent differences were found for individual MMPs and TIMPs, but MMP-2/TIMP-2 (discovery/validation: p = 0.004; p = 0.02) and MMP-14/TIMP-2 ratios (discovery/validation: p < 0.001; p = 0.04) were consistently decreased in sCAA, compared to controls. Moreover, MMP-14 was decreased in symptomatic D-CAA (p = 0.03), compared to controls. The MMP-14/TIMP-1 (p = 0.03) and MMP-14/TIMP-2 (p = 0.04) ratios were decreased in symptomatic D-CAA compared to controls and also compared to pre-symptomatic D-CAA (p = 0.004; p = 0.005, respectively).
CONCLUSION
CSF MMP-2/TIMP-2 and MMP-14/TIMP-2 were consistently decreased in sCAA, compared to controls. Additionally, MMP-14/TIMP-2 levels were also decreased in symptomatic D-CAA, compared to both pre-symptomatic D-CAA and controls, and can therefore be considered a biomarker for sporadic and late-stage hereditary forms of CAA.
Identifiants
pubmed: 36717932
doi: 10.1186/s13195-023-01171-3
pii: 10.1186/s13195-023-01171-3
pmc: PMC9885599
doi:
Substances chimiques
Tissue Inhibitor of Metalloproteinase-2
127497-59-0
Tissue Inhibitor of Metalloproteinase-1
0
Matrix Metalloproteinase 14
EC 3.4.24.80
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Subventions
Organisme : NINDS NIH HHS
ID : R01 NS104147
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
EMBO J. 1998 Sep 1;17(17):5238-48
pubmed: 9724659
J Cereb Blood Flow Metab. 2016 Sep;36(9):1481-507
pubmed: 27323783
J Neurochem. 2003 Jun;85(5):1208-15
pubmed: 12753080
J Alzheimers Dis. 2015;48(3):711-20
pubmed: 26402072
Cancer Res. 2001 May 1;61(9):3610-8
pubmed: 11325829
Stroke. 2011 May;42(5):1345-50
pubmed: 21454822
Biochem J. 2003 Sep 15;374(Pt 3):739-45
pubmed: 12755684
Amyloid. 2011 Mar;18(1):3-9
pubmed: 21261556
J Neurol Sci. 2005 Mar 15;229-230:249-54
pubmed: 15760647
Acta Neuropathol Commun. 2020 Jul 6;8(1):99
pubmed: 32631441
Neurobiol Dis. 2007 Dec;28(3):304-15
pubmed: 17761425
J Neuropathol Exp Neurol. 2002 Mar;61(3):282-93
pubmed: 11895043
Eur Respir J. 2011 Jul;38(1):191-208
pubmed: 21177845
Acta Neuropathol. 2009 Jul;118(1):103-13
pubmed: 19319544
EMBO J. 2001 Sep 3;20(17):4782-93
pubmed: 11532942
Biomolecules. 2021 Oct 11;11(10):
pubmed: 34680129
Biometals. 2017 Oct;30(5):797-807
pubmed: 28871443
Cancer Res. 1995 Jun 15;55(12):2548-55
pubmed: 7780967
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
Brain Pathol. 2008 Apr;18(2):240-52
pubmed: 18363935
Stroke. 2004 Jun;35(6):e159-62
pubmed: 15105518
J Biol Chem. 2004 Mar 5;279(10):8592-601
pubmed: 14681236
J Biol Chem. 2015 Jun 12;290(24):15078-91
pubmed: 25897080
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
J Biol Chem. 1997 Oct 10;272(41):25511-7
pubmed: 9325265
Nat Rev Neurol. 2020 Jan;16(1):30-42
pubmed: 31827267
Sci Rep. 2021 Jun 28;11(1):13376
pubmed: 34183752
Cancer Res. 1996 Jun 15;56(12):2707-10
pubmed: 8665498
Alzheimers Dement. 2022 Jan;18(1):10-28
pubmed: 34057813
J Cell Biochem. 1999 Nov 1;75(2):346-55
pubmed: 10502306
Rev Neurosci. 2014;25(5):641-51
pubmed: 24870607
Cell Mol Life Sci. 2019 Aug;76(16):3167-3191
pubmed: 31197405
Neuropathol Appl Neurobiol. 2017 Oct;43(6):492-504
pubmed: 27543695
J Alzheimers Dis. 2015;49(4):893-903
pubmed: 26599057
J Cell Sci. 2003 Oct 1;116(Pt 19):3905-16
pubmed: 12915589
Biochim Biophys Acta. 2010 Jan;1803(1):55-71
pubmed: 20080133
Neurobiol Aging. 2015 Nov;36(11):2963-2971
pubmed: 26248866
J Biol Chem. 2006 Aug 25;281(34):24566-74
pubmed: 16787929